Table 3.
Treatment related adverse events (Grade 3) and common grade 1 and 2 adverse events.
| Grade 3 SF1126-related adverse events | |||
|---|---|---|---|
|
| |||
| AE | Dose (mg/m2) | Grade 3 (n = 9) | |
| Generalised oedema | 90 | 1(11.1%) | |
| Alkaline phosphatase increased | 140 | 1(11.1%) | |
| Diarrhoea | 180 | 1(11.1%) | |
| Muscular weakness | 240 | 1(11.1%) | |
| Hypoglycaemia | 320 | 1(11.1%) | |
| Haemoglobin decreased | 430 | 1(11.1%) | |
| Pruritus/urticaria | 630 | 1(11.1%) | |
| Hypokalaemia | 840 | 1(11.1%) | |
| Hypersensitivity | 1110 | 1(11.1%) | |
| Grade 1 and 2 SF1126-related adverse events | |||||
|---|---|---|---|---|---|
| Nausea | 38.5% | Chills | 17.9% | ||
| Fatigue | 35.9% | Anorexia | 12.8% | ||
| Vomiting | 30.8% | Anaemia | 12.8% | ||
| Diarrhoea | 28.2% | Puritus | 12.8% | ||
| Pyrexia | 28.2% | Headache | 12.8% | ||